e-learning
resources
Virtual 2020
Pre-Congress Content
Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study.
M. Luzietoso (PARIS CEDEX 18, France), M. Ghanem (PARIS CEDEX 18, France), P. Le Guen (PARIS CEDEX 18, France), C. Taillé (PARIS CEDEX 18, France)
Source:
Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Session:
Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Session type:
E-poster session
Number:
2258
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Luzietoso (PARIS CEDEX 18, France), M. Ghanem (PARIS CEDEX 18, France), P. Le Guen (PARIS CEDEX 18, France), C. Taillé (PARIS CEDEX 18, France). Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study.. 2258
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Predictor of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study.
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis
Source: Eur Respir J, 56 (4) 2000151; 10.1183/13993003.00151-2020
Year: 2020
Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
Stopping
versus
continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)
Source: Eur Respir J, 59 (1) 2100396; 10.1183/13993003.00396-2021
Year: 2022
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021
Year: 2021
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Mepolizumab is effective in severe eosinophilic asthmatics: an Austrian real-life study.
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Omalizumab versus mepolizumab in severe asthma: a propensity score matched efficiency retrospective cohort study
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Super-responder analysis and real-world one year effectiveness of benralizumab in severe eosinophilic asthma
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Real-life treatment of severe eosinophilic asthma with mepolizumab
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020
Development of asthma in patients with eosinophilic bronchitis: prospective follow up study
Source: Eur Respir J 2002; 20: Suppl. 38, 51s
Year: 2002
A weight-based exacerbation dose-response analysis of mepolizumab in severe asthma with eosinophilic phenotype
Source: International Congress 2016 – Asthma management
Year: 2016
Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept